Guardant Health Stock Price, News & Analysis

Guardant Health, Inc. (Nasdaq: GH) has appointed Chris Freeman as the Chief Commercial Officer for its oncology business, effective June 8, 2021. Freeman brings extensive experience in managing pharmaceutical brands, which will aid in the company's efforts to expand its oncology portfolio for advanced and early-stage cancers. CEO Helmy Eltoukhy emphasized Freeman's role in developing commercial strategies to enhance growth across various market segments.

Guardant Health reveals promising early results from the LUNAR-2 blood test at the 2021 ASCO Annual Meeting, demonstrating a 91% sensitivity for detecting early-stage colorectal cancer (CRC) with a specificity of 94%. With only 68% of adults over 50 screened for CRC, this test may improve compliance with CDC goals. The ECLIPSE trial, a 10,000-patient study, is underway to validate these findings and support FDA approval. Guardant's CEO emphasizes the test's effectiveness in both asymptomatic and symptomatic patients, showcasing its potential for clinical adoption in average-risk populations.

Guardant Health announces FDA approval for its Guardant360 CDx test, the first liquid biopsy companion diagnostic for KRAS G12C mutation profiling in patients with non-small cell lung cancer (NSCLC). This approval, based on CodeBreaK 100 trial data, identifies patients eligible for LUMAKRAS™ (sotorasib), a targeted therapy for KRAS G12C mutation. Lung cancer is the leading cancer death cause in the U.S., and this development enhances personalized treatment options significantly.

Guardant Health, Inc. (Nasdaq: GH) has filed a lawsuit against Natera, Inc. for false advertising and unfair competition related to misleading claims about Guardant's new oncology test, Guardant Reveal™. The lawsuit seeks to prevent Natera from disseminating false information and demands corrective actions. Guardant Reveal™ is a groundbreaking blood-only liquid biopsy test designed to help early-stage colorectal cancer survivors detect residual disease and recurrences. This legal action arises from allegations that Natera misrepresents the test's efficacy, impacting patient treatment opportunities.

Guardant Health announces FDA approval for the Guardant360^®CDx liquid biopsy test, the first companion diagnostic for Janssen Biotech’s RYBREVANT™. Designed for tumor mutation profiling in non-small cell lung cancer (NSCLC), it identifies patients with EGFR exon 20 insertion mutations who may benefit from targeted therapy after chemotherapy. With lung cancer being the leading cause of cancer death, this approval marks a significant advancement in treatment options. The Guardant360 CDx test offers rapid genomic results from a blood draw, enhancing oncologists' ability to personalize treatment for patients.

Guardant Health, a leader in precision oncology, will participate virtually in two upcoming investor conferences. The first is the William Blair 41st Annual Growth Stock Conference on June 1, featuring a fireside chat at 12:00 PM PT. The second is the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, also at 12:00 PM PT.

Interested investors can access live and archived webcasts of these events via the company’s website. Guardant Health is known for its innovative blood tests and data analytics aimed at improving cancer care and patient outcomes.

Guardant Health (Nasdaq: GH) presented data at the 2021 ASCO Annual Meeting showcasing advancements in precision oncology through its blood tests. With 20 abstracts, the data emphasized the efficacy of blood-based genomic profiling in early-stage cancer screening and treatment monitoring. Key findings included a 91% sensitivity for early-stage colorectal cancer detection via the LUNAR-2 test and high predictive value of the Guardant Reveal test in detecting minimal residual disease. These innovations aim to enhance treatment decisions and patient outcomes in cancer care.

Guardant Health reported a revenue of $78.7 million for Q1 2021, marking a 17% increase year-over-year. The company conducted 18,390 clinical tests, a 21% increase, but biopharmaceutical tests declined by 33%. The launch of Guardant Reveal for colorectal cancer monitoring and the receipt of ADLT status for the Guardant360® test are significant highlights. However, operating expenses rose 93% to $157.8 million, leading to a net loss of $109.7 million. Looking ahead, Guardant expects full-year revenue between $360 million and $370 million, indicating 26%-29% growth.

Guardant Health (Nasdaq: GH) has appointed Craig Eagle, MD, as its new Chief Medical Officer (CMO). Dr. Eagle brings extensive experience in oncology from roles at Genentech and Pfizer, where he led medical affairs and clinical trial operations. His appointment aims to enhance Guardant Health's mission of advancing precision oncology and improving patient access to diagnostics. Dr. Eagle expressed enthusiasm for contributing to innovative cancer care strategies. Guardant Health specializes in liquid biopsy tests that target cancer detection and treatment at various stages.